Shots:

• The collaboration will explore Alnylam’s ALN-AAT02 and Dicerna’s DCR-A1AT- each in P-I/II development for the treatment of alpha-1 liver disease. Dicerna will lead the global clinical development and commercialization (US only) of its DCR-A1AT and Alnylam’s ALN-AAT02
• Post P-III completion- Alnylam retains an option to commercialize the selected candidate outside the US. If Alnylam exercises its opt-in right- both the companies will pay royalties to each other based on the commercialization of the product and if it waives its option- Alnylam will receive milestones and royalties while Dicerna retain global rights to commercialize the selected candidate
• Additionally- companies have completed a non-exclusive IP cross-license agreement for the development and commercialization of Alnylam’s lumasiran and Dicerna’s nedosiran for PH. Under the cross-license agreement- Alnylam will pay royalties to Dicerna on the global sales of lumasiran and Dicerna will pay royalties to Alnylam on global sales of nedosiran

Click here ­to­ read full press release/ article | Ref: Alnylam | Image: Dicerna